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Summary
Background:  It  has  been  suggested  that  depressed  persons  have  increased  oxidative  stress  and
decreased  anti-oxidant  defences.  8-Hydroxy-2′-deoxyguanosine  (8-OHdG)  and  F2-isoprostanes,
measures of  oxidative  DNA  and  lipid  damage  respectively,  are  among  the  most  reliable  oxidative
stress markers,  but  studies  on  their  association  with  depression  show  conﬂicting  results.  This
meta-analysis  quantiﬁes  the  association  between  depression  and  these  markers  and  explores
factors that  may  explain  inconsistencies  in  the  results.
Methods:  A  systematic  literature  search  was  conducted  in  PubMed,  EMBASE  and  PsycINFO.  Stud-
ies assessing  the  association  of  8-OHdG  or  F2-isoprostanes  with  elevated  depressive  symptoms,
major depressive  disorder  (MDD)  or  bipolar  disorder  (BD)  were  pooled  in  two  random-effect
models.
Results: The  pooled  effect  size  (Hedges’  g)  for  the  association  of  depression  with  oxidative  stress
was 0.31  (p  =  0.01,  I2 =  75%)  for  8-OHdG  (10  studies,  1308  subjects)  and  0.48  (p  =  0.001,  I2 =  73%)
for F2-isoprostanes  (8  studies,  2471  subjects),  indicating  that  both  markers  are  increased  in
depression.  There  was  no  indication  of  publication  bias  for  either  marker.  The  F2-isoprostane
results did  not  differ  by  type  of  depression,  biological  specimen,  laboratory  method  or  quality,
however subgroup  analyses  in  the  8-OHdG  studies  showed  signiﬁcantly  stronger  associations  in
plasma/serum  vs.  urine  samples  (p  <  0.01),  in  measurements  performed  with  immuno-assay  vs.
chromatography—mass  spectrometry  (p  <  0.01)  and  weaker  associations  in  high  quality  studies
vs. low  (p  =  0.02).
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Conclusion:  This  meta-analysis  ﬁnds  that  oxidative  stress,  as  measured  by  8-OHdG  and  F2-
isoprostanes,  is  increased  in  depression.  Larger-scale  studies  are  needed  to  extend  the  evidence
on oxidative  stress  in  depression,  and  examine  the  potential  impact  of  treatment.
© 2014  Elsevier  Ltd.  All  rights  reserved.
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I1. Introduction
Depression  is  a  leading  cause  of  morbidity  worldwide  (Vos
et  al.,  2012).  Depression  is  highly  prevalent  (Kessler  et  al.,
2003)  and  has  a  profound  impact  on  functioning  and  qual-
ity  of  life  (Bijl  and  Ravelli,  2000)  as  well  as  on  somatic
health.  Sufferers  are  at  higher  risk  of  diseases  that  are  usu-
ally  associated  with  increasing  age  such  as  cardiovascular
disease  (Nicholson  et  al.,  2006),  obesity  (Luppino  et  al.,
2010),  diabetes  (Mezuk  et  al.,  2008),  cancer  (Chida  et  al.,
2008),  cognitive  impairment  (Barnes  et  al.,  2006)  and  have
a  higher  all-cause  mortality  rate  (Cuijpers  et  al.,  2014).  It
is  hypothesized  that  increased  metabolic  stress  and  accel-
erated  cellular  ageing  may  be  underlying  pathways  that
contribute  to  this  poorer  physical  health  in  individuals  with
depression  (Wolkowitz  et  al.,  2011b).  A  fast  growing  body  of
evidence  suggests  the  involvement  of  a  speciﬁc  component
of  metabolic  stress,  oxidative  stress,  in  the  pathophysiology
of  depression  (Maes  et  al.,  2011).
Oxidative  stress  refers  to  the  biologically  damaging
effects  of  free  radicals  (Valko  et  al.,  2007).  The  produc-
tion  of  free  radicals,  or  reactive  oxygen  species  (ROS),  is
a  normal  process  in  aerobic  metabolism  and  ROS  perform
a  number  of  physiological  roles  in  cellular  signalling  and  in
the  defence  against  pathogens.  However,  when  present  in
excess,  ROS  cause  damage  to  lipids,  proteins  and  DNA,  and
can  ultimately  result  in  cell  death.  Oxidative  stress  is  a  well-
recognized  mechanism  in  ageing  and  disease.  It  has  been
shown  to  play  a  role  in  the  pathophysiology  of  —  among  oth-
ers  —  cardiovascular  disease,  diabetes  mellitus,  cancer  and
Alzheimer’s  disease  (Valko  et  al.,  2007).  Additionally,  there
is  evidence  suggesting  that  oxidative  stress  may  be  increased
in  a  number  of  psychiatric  disorders,  including  depression
(Pandya  et  al.,  2013).
A  recent  meta-analysis  pooling  data  from  studies  with  dif-
ferent  oxidative  stress  markers  suggests  oxidative  stress  is
increased  and  antioxidant  defences  are  decreased  in  depres-
sion  (Palta  et  al.,  2014).  In  line  with  these  ﬁndings,  increased
nitric  oxide  (NO)  and  lipid  peroxidation,  as  measured  by
thiobarbituric  acidic  reactive  substance  (TBARS)  assay,  have
also  been  found  in  patients  with  bipolar  disorder,  however
these  patients  did  not  differ  from  controls  in  anti-oxidant
enzymes  levels  (Andreazza  et  al.,  2008).  Overall,  these
studies  suggest  that  oxidative  stress  is  increased  in  major
depressive  disorder  and  bipolar  disorder.
There  is  a  wide  range  of  oxidative  stress  biomarkers  and
laboratory  techniques  available,  each  of  which  has  its  own
strengths  and  limitations  (Dalle-Donne  et  al.,  2006).  To  date
there  is  no  consensus  on  the  most  appropriate  biomarkers
of  oxidative  stress  in  general  and  the  validity  of  many  of
those  in  use  is  to  still  be  established.  ROS  have  a  short  half-
life,  making  measurement  difﬁcult.  Levels  of  antioxidants,
o
t
t
citamins  or  anti-oxidant  enzymes  are  informative,  but
eﬂect  only  one  side  of  redox  homeostasis,  leaving  the
uestion  unanswered  whether  decreased  levels  are  actu-
lly  also  indicative  of  increased  oxidative  damage.  Studies
how  quite  consistently  that  lipid  peroxidation  reﬂected  by
alondialdehyde  (MDA)  measured  with  the  TBARS  assay  is
ncreased  in  depression  (Palta  et  al.,  2014) and  in  bipolar
isorder  (Andreazza  et  al.,  2008).  However  this  commonly
sed  method  also  has  well  recognized  limitations:  MDA  is  not
 speciﬁc  product  of  lipid  peroxidation,  and  the  TBARS  assay
tself  can  generate  MDA,  causing  overestimation  of  levels.
DA  therefore  cannot  be  considered  an  optimal  represen-
ation  of  oxidative  stress  in  vivo  (Meagher  and  FitzGerald,
000;  Dalle-Donne  et  al.,  2006).
The  current  study  focusses  on  two  important  measures
f  oxidative  damage  that  have  already  been  widely  stud-
ed  in  somatic  disease  and  are  the  subject  of  an  increasing
umber  of  recent  publications  on  depression:  8-hydroxy-2′-
eoxyguanosine  (8-OHdG)  and  F2-isoprostanes.  The  majority
f  the  currently  available  literature  on  these  markers  in
epression  was  not  included,  or  not  yet  available  for
nclusion,  in  the  previous  meta-analyses  on  this  subject.
-OHdG  and  F2-isoprostanes  reﬂect  oxidative  damage  to
NA  and  lipids  respectively.  8-OHdG  is  an  oxidized  deriva-
ive  of  deoxyguanosine  and  it  is  both  the  most  abundant
nd  most  investigated  DNA  lesion.  It  has  recognized  muta-
enic  properties  and  has  been  linked  to  —  among  others  —
he  development  of  cancer  (Valavanidis  et  al.,  2009).  F2-
soprostanes,  oxidized  derivatives  of  arachidonic  acid,  have
ome  to  be  considered  the  preferred  approach  to  assess
xidative  stress  in  vivo  and  lipid  peroxidation  in  particular
Niki,  2014).
Several  studies  have  found  elevated  levels  of  F2-
soprostanes  (Dimopoulos  et  al.,  2008;  Yager  et  al.,  2010;
hung  et  al.,  2013)  and  8-OHdG  (Irie  et  al.,  2005;  Forlenza
nd  Miller,  2006)  in  patients  with  depression,  but  these  ﬁnd-
ngs  have  not  been  consistent  (Yi  et  al.,  2012;  Rawdin  et  al.,
013).  Earlier  studies  did  not  systematically  explore  to  what
xtent  the  (conﬂicting)  ﬁndings  are  due  to  e.g.  the  lab-
ratory  methods,  biological  specimens  used  for  oxidative
tress,  or  the  extent  to  which  studies  took  potential  con-
ounders  such  as  health  and  lifestyle  factors  into  account.
he  present  study  extends  the  current  evidence-base  by
ystematically  meta-analysing  the  literature  on  two  robust
arkers  of  oxidative  stress,  8-OHdG  and  F2-isoprostanes,
nd  their  association  with  depression  (major  depressive  dis-
rder,  bipolar  disorder  and  elevated  depressive  symptoms).
n  addition,  by  conducting  subgroup  analyses  based  on  type
f  depression,  biological  specimen,  laboratory  method  used
o  measure  oxidative  stress,  correction  for  confounders  and
he  quality  of  studies,  this  study  aims  to  identity  factors  that
ontribute  to  the  inconsistent  ﬁndings  of  individual  studies.
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I66  
. Methods
.1.  Literature  search  and  study  selection
ystematic  searches  of  the  literature  were  conducted  in  the
atabases  PubMed,  EMBASE  and  PsycINFO  up  to  January  8th
014  with  search  terms  covering  major  depressive  disorder,
ipolar  disorder  and  depressive  symptoms  combined  with  8-
HdG  and  F2-isoprostanes  respectively,  taking  into  account
 wide  range  of  synonyms  used  for  these  markers.  A  full  list
f  search  terms  is  reported  in  Appendix  A.  No  limitations
n  the  search  strategy  were  set.  The  search  results  were
eviewed  by  two  independent  reviewers  (CNB  and  MB)  by
creening  title  and  abstract,  followed  by  a  full  text  review.
isagreements  were  settled  by  discussion.
Studies  were  eligible  for  inclusion  if  they:
1)  contained  a  measurement  of  8-OHdG  or  F2-isoprostanes
in  any  body  ﬂuid  or  tissue  in  live  human  adult  subjects;
2)  deﬁned  major  depressive  disorder  (MDD)  or  bipolar  dis-
order  (BD)  according  to  DSM-IV  or  ICD-10  criteria  or
assessed  depressive  symptoms  using  a  validated  instru-
ment;
3)  reported  (or  were  able  to  provide)  sufﬁcient  information
to  calculate  an  effect  size  for  the  difference  between
levels  of  the  oxidative  stress  markers  in  control  subjects
and  subjects  with  depression.
An  assessment  of  the  references  of  the  included  studies
s  well  as  a  search  of  their  citations  in  the  PubMed  database
as  performed  to  identify  any  additional  studies.
.2.  Data  extraction  and  risk  of  bias  assessment
wo  authors  (CNB  and  MB)  independently  extracted  the
tudy  characteristics  (including  among  others  biological
pecimen,  age  and  sex  distribution)  and  results  from  each
tudy  using  a  predesigned  collection  form  (see  Appendix  B).
he  results  extracted  included  means,  standard  deviations
f  oxidative  stress  markers  in  patient  and  control  groups
or  alternative  results  sufﬁcient  to  calculate  an  effect  size)
nd  an  assessment  of  correction  for  potential  confounders
age,  sex,  ethnicity,  socio-economic  status,  smoking,  alco-
ol  use,  body  mass  index  (BMI),  physical  activity,  somatic
isease  and  antidepressant  or  mood  stabilizer  use).  Authors
f  studies  that  did  not  contain  sufﬁcient  information  (means,
tandard  deviations  or  standard  errors  and  number  of  sub-
ects)  to  calculate  an  effect  size  were  contacted  with  a
equest  for  additional  data.  Authors  of  studies  who  only
eported  results  on  depressive  symptoms  as  continuous  vari-
bles  were  requested  to  perform  additional  analyses  using  a
ichotomized  classiﬁcation  of  a  depressed  and  control  group
ased  on  the  appropriate  cut-off  for  the  instrument  used  to
ssess  depressive  symptoms.  Authors  of  studies  whose  origi-
al  articles  did  not  contain  adjusted  results  were  contacted
ith  a  request  to  perform  additional  analyses  adjusting  for
s  many  of  the  following  confounders  if  available:  age,
ex,  socio-economic  status  or  education,  ethnicity,  smok-
ng,  alcohol  use,  BMI;  physical  activity,  presence  of  somatic
isease  and  antidepressant  or  mood  stabilizer  use.  If  mul-
iple  adjusted  analyses  had  been  conducted,  the  results
O
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orrected  for  the  largest  number  of  potential  confounders
ere  included  in  the  meta-analysis.
The  quality  of  the  studies  was  determined  by  assessing
he  risk  of  bias  by  two  independent  reviewers  (CNB  and  MB)
n  three  domains:  selection  bias,  information  bias  and  con-
ounding.  Disagreements  were  settled  by  discussion.  Risk  of
ias  assessment  in  observational  studies  requires  consider-
tion  of  the  risks  speciﬁc  to  the  subject  of  study.  For  this
urpose  we  adapted  a  tool  by  Hayden  et  al.  (2006)  (see
ppendix  B).  Low  risk  of  bias  was  deﬁned  as  a  score  of  4.5
r  higher  (on  a 5  point  scale).
.3.  Meta-analysis
nalyses  were  performed  with  comprehensive  meta-analysis
CMA)  software  version  2.2.064.  Effect  sizes  (Hedges’  g)
ere  calculated  and  pooled  using  a  random  effects  model,  as
onsiderable  heterogeneity  was  expected.  A  p-value  <  0.05
as  considered  signiﬁcant.
Possible  publication  bias  was  tested  by  inspecting  the
unnel  plot,  by  the  statistical  signiﬁcance  of  the  Egger’s
est  of  the  intercept  (Sterne  and  Egger,  2001)  and  Duval  and
weedie’s  (2000)  trim  and  ﬁll  procedure.
To  examine  heterogeneity,  the  I2-statistic  was  calculated.
alues  of  25%,  50%  and  75%  indicate  low,  moderate  and
igh  heterogeneity,  respectively  (Higgins  et  al.,  2003).  The
5%  conﬁdence  intervals  around  I2 (Ioannidis  et  al.,  2007)
ere  calculated  using  the  non-central  chi-squared-based
pproach  within  the  heterogi  module  for  STATA  version  11.0
or  Mac.
When  a minimum  of  three  samples  per  subgroup  was
vailable,  analyses  were  performed  categorized  by:  type  of
epression  (MDD,  BD,  depressive  symptoms  above  the  ques-
ionnaire  cut-off  level),  laboratory  method  for  measuring
xidative  stress  (chromatography  [coupled  to  either  mass-
pectrometry  or  electrochemical  detection]  vs.  immuno-
ssay),  biological  specimen  used  (urine,  blood[product]  or
ther),  low  or  high  risk  of  bias  score,  and  adjusted  versus
nadjusted  results.  Studies  that  accounted  for  at  least  age,
ex  and  one  life-style  variable  (either  by  matching,  restric-
ion,  adjustment  or  testing  for  baseline  group  differences)
ere  deﬁned  as  corrected  for  confounding.
. Results
.1.  Search  results,  study  characteristics  and  risk
f bias  scoring
.1.1.  8-OHdG
fter  removal  of  duplicates,  79  records  were  assessed  based
n  title  and  abstract.  The  full-text  of  39  of  these  records
as  retrieved  for  further  assessment.  Of  these  studies  6  did
ot  report  sufﬁcient  information  in  the  original  articles  to
alculate  an  effect  size  and  none  was  provided  by  authors
n  request  (Irie  et  al.,  2001,  2002,  2003;  Maes  et  al.,  2009;
ida  et  al.,  2011;  Ceylan  et  al.,  2013).  In  2  studies  both  8-
HdG  and  depression  were  measured  but  the  association
etween  the  two  was  not  the  focus  of  study  and  therefore
ot  analyzed  (Wu  et  al.,  2009;  Ceprnja  et  al.,  2011),  nor
as  this  data  provided  on  request.  In  total  10  studies  met
Oxidative  stress  in  depression:  A  meta-analysis  
8-OHdG in  depression 
F2- isop rosta nes in d epression  
PubMed  41  re cord s 
EMBASE 73 records 
PsycInfo  15  record s 
129 records  in  total   
79 records  after  duplicates  remove d 
79 records  scr eened  on  title 
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21 no  hu mans 
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 3 review 
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30 full-te xt articles  assess ed 
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1 duplicate data 
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Figure  1  Flowchart  of  the  selection  of  studies  on  8-OHdG  or
F2-isoprostanes  in  depression  (major  depressive  disorder,  bipo-
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all  criteria  for  inclusion;  4  studies  on  depressive  symptoms
(Kupper  et  al.,  2009;  Wei  et  al.,  2009a,b;  Yi  et  al.,  2012),  2
studies  on  MDD  (Irie  et  al.,  2005;  Forlenza  and  Miller,  2006),
3  studies  on  BD  (Ceylan  et  al.,  2012;  Soeiro-de-Souza  et  al.,
2013;  Huzayyin  et  al.,  2014)  and  1  study  with  both  MDD  and
BD  patients  (Jorgensen  et  al.,  2013)  (Fig.  1).  Two  of  the
included  studies  (Yi  et  al.,  2012;  Jorgensen  et  al.,  2013)
provided  additional  data  on  request.
The  10  studies  (Irie  et  al.,  2005;  Forlenza  and  Miller,  2006;
Kupper  et  al.,  2009;  Wei  et  al.,  2009a,b;  Yi  et  al.,  2012;
Ceylan  et  al.,  2012;  Soeiro-de-Souza  et  al.,  2013;  Jorgensen
et  al.,  2013;  Huzayyin  et  al.,  2014)  included  a  total  of  579
subjects  with  depression  (332  with  depressive  symptoms
[scoring  above  the  cut-off  of  the  instrument  used],  141  with
MDD,  106  with  BD)  and  729  controls.  All  included  studies
were  published  between  2005  and  2014.  The  studies  include
samples  from  the  general  population  (N  =  2),  psychiatric  in-
and  outpatient  clinics  (N  =  4),  hospital  oncology  (N  =  2)  and
heart  failure  departments  (N  =  1)  and  1  unreported  source
3
T
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Table  1).  Risk  of  bias  was  scored  as  low  in  3 studies  and
igh  in  7  studies  (Appendix  C).
.1.2.  F2-isoprostanes
fter  removal  of  duplicates,  221  records  were  assessed
ased  on  title  and  abstract.  The  full-text  of  30  of  these
ecords  was  retrieved  for  further  assessment.  Of  these  stud-
es  1  did  not  report  sufﬁcient  information  in  the  original
rticle  to  calculate  an  effect  size  and  none  was  provided  by
uthors  on  request  (Freund-Levi  et  al.,  2011). In  one  study
oth  F2-isoprostanes  and  depression  were  measured  but  the
ssociation  between  the  two  was  not  the  focus  of  study  and
herefore  not  analyzed  nor  provided  on  request  (Janicki-
everts  et  al.,  2009).  The  samples  of  Rawdin  et  al.  (2013)
nd  Wolkowitz  et  al.  (2011a)  overlap,  leaving  8  original  sam-
les  eligible  for  inclusion,  3  on  depressive  symptoms  (Chung
t  al.,  2009;  Segal  et  al.,  2012;  Milaneschi  et  al.,  2013)  and
 on  MDD  (Fig.  1).  Six  of  the  included  studies  provided  addi-
ional  data  upon  request  (Chung  et  al.,  2009,  2013;  Yager
t  al.,  2010;  Wolkowitz  et  al.,  2011a;  Segal  et  al.,  2012;
ilaneschi  et  al.,  2013).
The  8  studies  (Dimopoulos  et  al.,  2008;  Chung  et  al.,
009,  2013;  Yager  et  al.,  2010;  Wolkowitz  et  al.,  2011a;
egal  et  al.,  2012;  Pomara  et  al.,  2012;  Milaneschi  et  al.,
013) include  a  total  of  293  subjects  with  depression  (144
ubjects  with  depressive  symptoms,  149  with  MDD)  and  2178
ontrols.  All  included  studies  were  published  between  2008
nd  2013.  The  studies  include  samples  of  adults  from  the
eneral  population  (N  = 2),  elderly  adults  form  the  general
opulation  (N  = 3),  psychiatric  outpatients  (N  =  1),  systemic
upus  erythematosus  (SLE)  patients  (N  =  1)  and  ﬁbromyalgia
atients  (N  =  1)  (Table  2).  Risk  of  bias  was  scored  as  low  in  3
tudies  and  high  in  5  studies  (Appendix  C).
.2.  Meta-analyses
.2.1.  8-OHdG
he  overall  effect  size  (Hedges’  g)  including  all  10  studies  on
-OHdG  in  the  meta-analysis  was  0.31  (95%  CI  0.06,  0.56),
2 =  75%  (95%  CI  58—86%)  indicating  8-OHdG  is  signiﬁcantly
ncreased  in  depression  (Fig.  2a  and  Table  3).  Egger’s  test
or  publication  bias  was  not  signiﬁcant  (p  =  0.69).  The  effect
ize  adjusted  for  publication  bias  by  Duval  and  Tweedie’s
rim  and  ﬁll  procedure  (two  trimmed  studies)  increased
arginally  to  0.37  (95%  CI  0.13,  0.61)  indicating  no  or  lit-
le  effects  of  publication  bias  (see  Appendix  D  for  funnel
lot).
Subgroup  analyses  in  the  8-OHdG  studies  showed  signif-
cantly  larger  effect  sizes  for  studies  that  were  conducted
n  plasma  or  serum  vs.  those  in  urine  (p  < 0.001)  and  stud-
es  that  were  performed  with  immuno-assays  vs.  those  with
hromatography  (p  =  0.006).  Studies  with  a  low  risk  of  bias
howed  a  signiﬁcantly  lower  effect  size  compared  to  stud-
es  with  a  higher  risk  of  bias  (p  =  0.02).  Subgroup  analyses  by
ype  of  depression  (depressive  symptoms  or  BD  vs.  MDD)  and
esults  corrected  and  uncorrected  for  confounders  revealed
o  signiﬁcant  differences  (Table  3)..2.2.  F2-isoprostanes
he  overall  effect  size  (Hedges’  g)  including  all  8  stud-
es  on  F2-isoprostanes  in  the  meta-analysis  was  0.48  (95%
168
 
C.N
.
 Black
 et
 al.
Table  1  Study  characteristics  of  the  included  studies  on  the  association  of  8-OHdG  with  major  depressive  disorder,  bipolar  disorder  and  depressive  symptoms.
8-OHdG Study
design
Sample
description
Depressive
disorder
Patients
N
Controls
N
Diagnostic
method
Biological
specimen
8-OHdG
analysis
Confoundersd Overall
correction
confounding
Effect size
Hedges’ g (95% CI)Socio
demo-
graphics
Life-
style
Somatic
disease
AD\mod
stabiliz-
ers
Forlenza and
Miller (2006)
CC General
population
MDD 62 85 DSM-IV (DISH) Serum ELISA + + + + + 0.47 (0.14, 0.80)
Irie et al. (2005) CC Psychiatric
outpatients
MDD 30 60 DSM-IV Leukocytes HPLC/ED − − − − − 0.76 (0.31, 1.21)
Jorgensen
et al.
(2013)
CC Psychiatric
department
MDDa 26 27 DSM-IV (MINI) Urine UPLC/MS ± ± − + + −0.07 (−0.81, 0.67)
CC  Psychiatric
department
MDDb 23 27 ICD-10
psychiatrist
Urine UPLC/MS ± ± + − + −0.10 (−0.85, 0.65)
CC  Psychiatric
department
BDc 6 27 ICD-10
psychiatrist
Urine UPLC/MS ± ± + − + −0.15 (−1.13, 0.82)
Ceylan et al.
(2012)
CC Not reported BD 36 14 DSM-IV (SCID) Blood nos GC/MS − − − − − −0.23 (−0.83, 0.38)
Soeiro-de-Souza
et al. (2013)
C Psychiatric
outpatients
BD 50 50 DSM-IV (SCID) Plasma ELISA ± − − + − 1.15 (0.74, 1.57)
Huzayyin et al.
(2014)
CC Specialist
psychiatric
clinic
BD 14 16 DSM-IV (SADS-L) Lymph-
oblasts
ELISA ± − − − − 0.17 (−0.53, 0.87)
Kupper et al.
(2009)
C Heart failure
outpatients
DS 38 72 BDI ≥ 10 Serum ELISA − − − − − 0.14 (−0.25, 0.53)
Wei et al. (2009a) CC Oncology
department
DS 52 30 HAM-D ≥ 20 Serum ELISA ± ± + − + 0.81 (0.35, 1.28)
Wei et al. (2009b) CC Oncology
department
DS 63 43 HAM-D ≥ 20 Serum ELISA + − + − + 0.64 (0.25, 1.04)
Yi et al. (2012)
Males C Municipal
workers
DS 105 196 CES-D ≥ 16 Urine HPLC/ED ± + − + + −0.01 (−0.25—0.23)
Females  C Municipal
workers
DS 74 136 CES-D ≥ 16 Urine HPLC/ED ± + + + + −0.09 (−0.37, 0.19)
BD, bipolar disorder; BDI, Beck Depression Inventory; C, cohort; CC, case—control; CES-D, Centre for Epidemiological Studies Depression Scale; DISH, Depression Interview and structured
Hamilton Interview; DS, depressive symptoms; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; ELISA, enzyme-linked immunosorbent assay GC/MS, gas chromatography/mass
spectrometry HAMD, Hamilton Depression Rating Scale; HPLC/ED, high-performance liquid chromatography/electrochemical detector; ICD-10, International Statistical Classiﬁcation of
Diseases and Related Health Problems; MDD, major depressive disorder; MINI, Mini International Neuropsychiatric Interview; NOS, not otherwise speciﬁed; SADS-L, Schedule for Affective
Disorders and Schizophrenia, lifetime version; SCID, structured clinical interview for DSM-IV; UPL/MS, ultra performance liquid chromatography/mass spectrometry.
a Subsample of patients in Jorgensen et al. (2013) described in the article as M-DEP (moderately depressed) patients.
b Subsample of patients in Jorgensen et al. (2013) described in the article as S-DEP (severely depressed patients unipolar only).
c Subsample of patients in Jorgensen et al. (2013) described in the article as S-DEP (severely depressed, bipolar only).
d Socio-demographics include age, sex, socio-economic status (income, education or other), ethnicity. Lifestyle: smoking, alcohol, BMI, physical activity. Somatic disease: presence
of (chronic) disease (cardiovascular, infectious, auto-immune or malignancy) that may inﬂuence oxidative stress levels. Antidepressant/mood stabilizers: current use. +, confounders is
accounted for; −, confounder is not accounted for; ±, some, but not all of the confounders in the category have been accounted for. Studies are deﬁned as corrected (+) if the have
accounted for age, sex and at least on life-style variable.
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Table  2  Study  characteristics  of  the  included  studies  on  the  association  between  F2-isoprostanes  and  major  depressive  disorder  and  depressive  symptoms.
F2-isops Study
design
Sample
description
Depressive
disorder
Patients N Controls N Diagnostic
method
Biological
specimen
F2-isoprostane
analysis
Confoundersa Overall
correction
confounding
Effect size
Hedges’ g (95% CI)Socio
demographics
Life-
style
Somatic
disease
AD\mood
stabilizers
Chung et al.
(2013)
CC General
population
MDD 18 36 DSM-IV
(SCID)
Urine  GC/MS ± ±  + + + 1.12 (0.53, 1.72)
Dimopoulos
et al. (2008)
CC General
population >60
years
MDD 33 33 DSM-IV
psychiatrist
Plasma ELISA ± ±  + + + 1.11 (0.60, 1.63)
Pomara et al.
(2012)
CC General
population >60
years
MDD 28 19 DSM-IV
(SCID)
CFS  ELISA ± ±  − − + 0.88 (0.28, 1.48)
Yager et al.
(2010)
CC General
popluation
MDD 57 74 DSM-IV
(DISH)
Serum ELISA + + + + + 0.45 (0.10, 0.80)
Wolkowitz
et al. (2011a)
CC Psychiatric
outpatients
MDD 13 14 DSM-IV
(SCID)
Plasma GC/MS + + + + + −0.16 (−0.89,
0.58)
Chung et al.
(2009)
CC Fibromyalgia
patients
DS 28 20 CES-D ≥ 16 Urine GC/MS − −  + − − 0.37 (−0.20, 0.94)
Milaneschi et al. (2013)
Males C General
population
70—79 years
DS  31 996 GDS ≥ 5
and/or AD
use
Urine RIA + + + − + 0.30 (−0.06, 0.66)
Females C DS 52 896 Urine RIA + + + − + −0.02 (−0.30,
0.26)
Segal et al.
(2012)
CC SLE patients DS 33 90 CES-D ≥ 16 Plasma GC/MS ± ±  − − + 0.38 (−0.02, 0.78)
AD, antidepressant; C, cohort; CC, case—control; CES-D, Centre for Epidemiological Studies Depression Scale; CFS, cerebrospinal ﬂuid; DISH, Depression Interview and structured Hamilton
Interview; DS, depressive symptoms; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; ELISA, enzyme-linked immunosorbent assay; GC/MS, gas chromatography/mass
spectrometry; GDS, geriatric depression scale; HAMD, Hamilton Depression Rating Scale; ICD-10, International Statistical Classiﬁcation of Diseases and Related Health Problems; MDD,
major depressive disorder; RIA, radio immuno assay; SCID, structured clinical interview for DSM-IV; SLE, systemic lupus erythematosus.
a Socio-demographics include age, sex, socio-economic status (income, education or other), ethnicity. Lifestyle: smoking, alcohol, BMI, physical activity. Somatic disease: presence
of (chronic) disease (cardiovascular, infectious, auto-immune or malignancy) that may inﬂuence oxidative stress levels. Antidepressant/mood stabilizers: current use. +, confounders is
accounted for; −, confounder is not accounted for; ±, some, but not all of the confounders in the category have been accounted for. Studies are deﬁned as corrected (+) if the have
accounted for age, sex and at least on life style variable.
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Table  3  Results  of  meta-analyses  on  the  association  of  8-OHdG  and  F2-isoprostanes  with  depressive  symptoms,  major  depressive  disorder  and  bipolar  disorder.
8-OHdG  N  studies  Hedges’  g  95%  CI  p  I2 95%  CI
All  studies  (depressive  symptoms,  MDD,  BD)  10  0.31  0.06,  0.56  0.01  75%  58—86%
Egger’s test  for  publication  biasa 10  0.69
Subgroup analyses  N  samples  Hedges’  g  95%  CI  pf I2 95%  CI
Depressionb Depressive  symptoms  4  0.27  −0.06,  0.60  0.67  78%  48—91%
MDD 3  0.37  0.01,  0.74  Reference  48%  0—83%
BD 4  0.28  −0.48,  1.05  0.83  83%  55—93%
Biological specimenc Urine  2  −0.05  −0.22,  0.12  0%  0—79%
Plasma/serum  6  0.52  0.18,  0.87  <0.01  75%  43—89%
Laboratory method Chromatography  4  0.05  −0.20,  0.31  50%  0—79%
Immunoassay  6  0.58  −0.28,  0.88  <0.01  66%  19—86%
Correction for  confounders Unadjusted  5  0.43  −0.07,  0.92  80%  53—92%
Adjusted 5  0.23  −0.04,  0.51  0.50  69%  36—85%
Risk of  bias  scored ‘‘Low’’  risk  of  bias  3  0.06  −0.15,  0.27  35%  0—74%
‘‘High’’  risk  of  bias  7  0.53  0.19,  0.87  0.02  72%  40—87%
F2-isoprostanese N  studies  Hedges’  g  95%  CI  p  I2 95%  CI
All  studies  (depressive  symptoms,  MDD)  8  0.48  0.19,  0.77  0.001  73%  47—86%
Egger’s test  for  publication  biasa 8  0.13
Subgroup analyses  N  samples  Hedges’  g  95%  CI  pf I2 95%  CI
Depression Depressive  symptoms  3  0.24  −0.05,  0.53  56%  0—86%
MDD 5  0.70  0.28,  1.12  0.08  66%  13—87%
Biological specimenc Urine  3  0.41  −0.06,  0.89  80%  48—92%
Plasma/serum  4  0.49  0.08,  0.89  0.82  67%  3—89%
Laboratory method Immunoassay  4  0.51  0.10,  0.92  81%  57—92%
Chromatography  4  0.45  0.00,  0.90  0.84  61%  0—87%
Correction for  confounders  NA
Risk of  bias  scored ‘‘Low’’  risk  of  bias  3  0.51  −0.10,  1.11  74%  40—89%
‘‘High’’ risk  of  bias  5  0.46  0.11,  0.81  0.90  77%  24—93%
BD, bipolar disorder; DS, depressive symptoms; MD, major depressive disorder; NA, not applicable; no or insufﬁcient studies to perform the subgroup analysis.
a See Appendix D for funnel plots.
b Jorgensen et al. (2013) is counted in two categories because it describes stratiﬁed analyses of both MDD and BD patients.
c studies using specimens from others sources were excluded from this analysis (Irie et al., 2005; Huzayyin et al., 2014; Pomara et al., 2012).
d See Appendix C for risk of bias scores.
e Results of sensitivity analyses, excluding Pomara et al. (2012) with specimens from CSF (cerebrospinal ﬂuid): all studies: Hedges’ g 0.44, p 0.004; Egger’s test: p 0.22. MDD: Hedges’ g
0.66, p between subgroups 0.17; immunoassay: Hedges’ g 0.44, p between subgroups 0.98, ‘‘High’’ risk of bias: Hedges’ g 0.39, p between subgroups 0.75.
f p value between subgroups.
Oxidative  stress  in  depression:  A  meta-analysis  
Figure  2  (a)  Meta-analysis  of  8-OHdG  in  depression  (major
depressive  disorder  [MDD],  bipolar  disorder  [BD]  and  depressive
symptoms  [DS])  with  effect  sizes  Hedges’  g  and  95%  conﬁdence
intervals  for  the  comparison  of  8-OHdG  levels  with  controls.  (b).
Meta-analysis  of  F2-isoprostanes  in  depression  (major  depres-
sive disorder  [MDD]  and  depressive  symptoms  [DS])  with  effect
sizes Hedges’  g  and  95%  conﬁdence  intervals  for  the  comparison
of F2-isoprostane  levels  with  controls.
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differences  between  studies  based  on  risk  of  bias,  with
the  studies  with  lower  risk  of  bias  ﬁnding  smaller  effects.
There  was  also  a signiﬁcant  difference  in  effect  size  in
the  subgroup  analyses  by  biological  specimen  (higher  inCI  0.19,  0.77),  I2 =  73%  (95%  CI  47—86%),  indicating  that
F2-isoprostanes  are  signiﬁcantly  increased  in  depression
(Fig.  2b  and  Table  3).  Egger’s  test  was  not  signiﬁcant
(p  =  0.13)  and  the  effect  size  adjusted  for  publication  bias
by  Duval  and  Tweedie’s  trim  and  ﬁll  procedure  (no  trimmed
studies)  was  unchanged,  indicating  no  signiﬁcant  effects  of
publication  bias  (see  Appendix  D  for  funnel  plot).
A  sensitivity  analysis  was  performed  excluding  one  study
(Pomara  et  al.,  2012)  as  this  study  measured  oxidative
stress  centrally  (in  cerebrospinal  ﬂuid)  as  opposed  to  periph-
eral  measurements  (blood  and  urine)  used  in  all  others.
Exclusion  of  this  study  did  not  affect  the  overall  results
(Hedges’  g  0.44,  p =  0.004;  Table  3).  Subgroup  analyses  in
F2-isoprostanes  showed  a  trend  level  difference  between
studies  assessing  depressive  symptoms  vs.  MDD  with  the  MDD
studies  showing  a  larger  effect  size  (p  =  0.08).  Subgroup  anal-
yses  by  biological  specimen  used,  laboratory  method  for
oxidative  stress  measurement  and  risk  of  bias  score  revealed
no  signiﬁcant  differences  (Table  3).  No  subgroup  analyses
were  performed  based  on  correction  for  confounders  as  only
one  study  was  deﬁned  as  uncorrected.171
.  Discussion
his  meta-analysis  found  that  both  oxidative  stress  mark-
rs,  8-OHdG  and  F2-isoprostanes,  are  increased  in  subjects
ith  depression  (major  depressive  disorder,  bipolar  disorder
nd  depressive  symptoms)  compared  to  controls,  with  effect
izes  in  the  small  to  moderate  range  (Cohen,  1988).  In  addi-
ion,  subgroup  analyses  of  the  8-OHdG  studies  revealed  that
ome  of  the  variation  in  the  results  may  be  explained  by
he  type  of  the  biological  specimen  and/or  the  laboratory
ethod  for  oxidative  stress  measurement,  and  that  studies
ith  lower  risk  of  bias  reported  signiﬁcantly  smaller  effect
izes.  Findings  for  F2-isoprostanes  however,  did  not  differ
hen  analyzed  by  type  of  depression,  biological  specimen,
aboratory  method  or  quality.
The  results  indicate  that  depression  is  associated  with
ncreased  oxidative  damage  to  DNA  and  lipids  (reﬂected
y  8-OHdG  and  F2-isoprostanes  respectively).  These  ﬁnd-
ngs  are  in  line  with  previous  meta-analytic  studies  that
eported  decreased  anti-oxidants  and  anti-oxidant  enzymes
n  unipolar  depression,  and  increased  oxidative  stress  in
oth  uni-  and  bipolar  depression  (Andreazza  et  al.,  2008;
alta  et  al.,  2014).  Previously  DNA  damage  in  bipolar  dis-
rder  has  been  reported  measured  by  increased  levels  of
NA  strand  breakage  with  the  comet  assay  (Andreazza
t  al.,  2007).  Oxidative  damage  to  proteins  determined
y  the  protein  carbonyl  assay  has  not  yet  been  as  widely
tudied,  but  increased  levels  have  been  reported  in  MDD
nd  BD  (Kapczinski  et  al.,  2011;  Magalhaes  et  al.,  2012),
owever  not  consistently  (Andreazza  et  al.,  2009;  Gubert
t  al.,  2013).  The  oxidative  stress  markers  used  in  this
eta-analysis  are  among  the  most  robust  markers  of  oxida-
ive  stress  currently  available  and  have  recognized  roles
n  the  pathophysiology  various  somatic  diseases  such  as
ardiovascular  disease,  cancer  and  diabetes  (Dalle-Donne
t  al.,  2006;  Valavanidis  et  al.,  2009).  8-OHdG  is  a  biologi-
ally  important  mutagenic  DNA  lesion,  while  F2-isoprostanes
re  known  to  be  increased  in  atherosclerotic  lesions  and
ay  also  be  biologically  active  in  the  pathogenesis  of
therosclerosis  (Ho  et  al.,  2013).  It  should  be  noted  that
lthough  both  markers  reﬂect  oxidative  damage  they  are
ot  necessarily  associated  with  each  other.  One  study
ncluded  in  our  meta-analysis  (Yager  et  al.,  2010)  found
o  correlation  between  the  two,  suggesting  that  8-OHdG
nd  F2-isoprostanes  reﬂect  speciﬁc  aspects  of  oxidative
mbalance.
Although  the  main  ﬁndings  of  this  study  are  unlikely
o  be  greatly  inﬂuenced  by  publication  bias,  considerable
eterogeneity  between  studies  was  found  for  both  8-OHdG
nd  F2-isoprostanes.  This  heterogeneity  may  be  explained
y  several  factors.  In  the  studies  that  examined  8-OHdG,
atients  in  three  bipolar  disorder  studies  (Ceylan  et  al.,
012;  Soeiro-de-Souza  et  al.,  2013;  Huzayyin  et  al.,  2014)
ere  not  all  currently  depressed,  but  some  were  in  a  manic
r  euthymic  state.  This  may  account  for  the  fact  that  two
f  these  studies’  results  have  the  highest  and  lowest  effect
izes  included  in  the  meta-analysis.  In  addition,  the  sub-
roup  analyses  in  8-OHdG  studies  demonstrated  signiﬁcant
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lasma/serum  than  in  urine)  and  by  laboratory  method  used
o  measure  oxidative  stress  (higher  in  immuno-assays  than
hromatography).  With  only  one  exception  however,  all  the
easurements  using  chromatography  were  done  in  urine
amples,  whereas  all  the  immuno-assays  for  the  measure-
ent  of  8-OHdG  in  were  done  in  plasma  or  serum.  Therefore,
t  cannot  be  determined  whether  this  difference  is  based
n  the  biological  specimen  or  laboratory  technique.  8-OHdG
evels  determined  by  immuno-assays  are  higher  than  those
easured  by  chromatography,  with  the  latter  considered  the
old  standard.  The  correlation  between  the  two  methods  is
enerally  high  (Yoshida  et  al.,  2002)  and  so  may  not  neces-
arily  affect  the  strength  of  the  association  with  depression.
t  has  been  reported  that  urinary  8-OHdG  levels  are  more
table  than  those  in  plasma  or  serum,  and  therefore  pos-
ibly  more  reliable  (Matsumoto  et  al.,  2008).  Although  the
ubgroup  analyses  may  help  to  explain  the  heterogeneity
bserved,  the  ﬁndings  should  be  interpreted  with  consider-
ble  caution,  as  the  number  of  studies  in  the  subgroups  is
mall.
This  meta-analysis  conﬁrms  oxidative  stress  markers  are
ncreased  in  subjects  with  depression  in  cross-sectional  stud-
es,  but  the  underlying  mechanisms  explaining  this  link  need
o  be  examined  further.  Many  behavioural  factors  that  are
elated  to  increased  exposure  to  ROS  (smoking,  alcohol  use,
verweight,  physical  activity)(Maritim  et  al.,  2003;  Dalle-
onne  et  al.,  2006;  Valko  et  al.,  2007)  are  also  associated
ith  depression  (Glassman  et  al.,  1990;  Abu-Omar  et  al.,
004;  Sullivan  et  al.,  2005;  Luppino  et  al.,  2010).  It  cannot
e  ruled  out  that  the  association  is  partially  driven  by  these
r  other  lifestyle  confounders.  The  majority  of  the  included
tudies  took  some,  but  few  took  all  of  these  potential  con-
ounders  into  account.  The  results  of  studies  that  did  correct
or  confounders  did  not  differ  signiﬁcantly  from  studies  that
id  not,  strengthening  the  observation  that  an  association
etween  depression  and  oxidative  stress  is  present  inde-
endent  of  these  life-style  factors.  The  observed  increased
evels  of  oxidative  stress  in  depression  might  be  under-
tood  within  the  concepts  of  allostasis  and  allostatic  load.
he  former  refers  to  the  physiological  adaptation  to  physi-
al,  psychological,  social  and  environmental  stressors.  The
atter  refers  to  the  physical  ‘‘wear  and  tear’’  induced  by
rolonged  exposure  to  the  stress  response  (McEwen  and
ingﬁeld,  2003).  Depression  has  been  found  to  be  associ-
ted  with  increased  ‘‘wear  and  tear’’  or  accelerated  cellular
geing  reﬂected  by  decreased  telomere  length  in  depressed
atients  (Verhoeven  et  al.,  2013).  Dysregulations  in  the
ajor  stress  systems  (hypothalamic-pituitary-adrenal  axis
ctivity,  autonomic  nervous  system  function  and  inﬂam-
atory  functions)  have  been  demonstrated  in  depression
Penninx  et  al.,  2013)  and  these  could  be  contributing  to
ncreased  oxidative  stress.  Oxidative  stress  is  closely  related
o  the  inﬂammatory  pathway  in  particular.  Pro-inﬂammatory
ytokines  are  produced  in  reaction  to  oxidative  stress  and
xidative  stress  in  turn  ampliﬁes  the  inﬂammatory  response.
igh  cortisol  levels  have  been  associated  with  increased
evels  of  oxidative  damage  (Joergensen  et  al.,  2011).  The
amage  caused  by  this  allostatic  load  experienced  dur-
ng  mood  episodes  is  hypothesized  to  render  an  individual
ore  vulnerable  to  developing  a  following  episode  and  at
igher  risk  to  develop  somatic  disease  (Maes  et  al.,  2011;
rande  et  al.,  2012).  The  brain  is  particularly  vulnerable  to
C
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xidative  damage  due  to  its  high  oxygen  consumption
nd  low  anti-oxidants  defences.  There  is  evidence  from
ost-mortem  studies  suggesting  that  in  depression  oxida-
ive  stress  is  increased  (Wang  et  al.,  2009;  Che  et  al.,
010;  Michel  et  al.,  2012)  and  anti-oxidants  are  decreased
Gawryluk  et  al.,  2011)  in  the  brain.
This  meta-analysis’  strength  lies  in  the  focus  on  robust
xidative  stress  markers  and  in  the  comprehensive  search
hat  was  conducted  to  identify  all  studies  on  the  association
f  8-OHdG  and  F2-isoprostanes  with  depression.  Through
dditional  data  requests  the  number  of  studies  eligible
or  inclusion  was  increased,  and  where  possible  adjusted
ata  was  obtained,  mitigating  the  effects  of  possible  pub-
ication  bias  and  increasing  the  reliability  of  the  overall
esults.
There  are  also  a  number  of  important  limitations.  As  is
pparent  from  the  number  of  included  studies  and  subjects
he  evidence  on  8-OHdG  and  F2-isoprostanes  in  depression
s  limited.  The  studies  that  were  excluded  because  they  only
eported  on  depressive  symptoms  as  a continuous  measure
Irie  et  al.,  2001,  2003;  Iida  et  al.,  2011)  all  found  a  positive
ssociation.  Therefore  it  is  most  likely  that  they  would  not
ave  altered  the  overall  result.  Furthermore,  the  covariates
sed  in  the  adjusted  analyses  varied  widely.  Therefore  it
as  not  possible  to  assess  the  effects  of  adjustment  on  the
esults  satisfactorily.  Information  on  diet  and  anti-oxidant
upplement  use  was  not  available  for  most  studies  and  there-
ore  it  cannot  be  ruled  out  this  factor  may  have  had  an
ffect.  In  addition,  the  use  of  antidepressants  or  mood  stabi-
izers  could  also  be  sources  of  confounding  that  were  often
ot  investigated.  There  is  some  evidence  to  suggest  that
ntidepressants,  lithium  and  other  mood  stabilizers  protect
gainst  oxidative  stress  (Behr  et  al.,  2012;  Khairova  et  al.,
012;  de  Sousa  et  al.,  2014)  Studies  addressing  their  effects
n  F2-isoprostanes  however  found  an  increase  (Chung  et  al.,
013)  or  no  effect  on  oxidative  stress  levels  (Rawdin  et  al.,
013).
In  conclusion,  the  ﬁnding  that  both  8-OHdG  and  F2-
soprostanes  are  increased  in  depression  strongly  suggests
hat  depression  is  accompanied  by  increased  oxidative  dam-
ge.  This  ﬁnding  supports  the  hypothesis  that  increased
etabolic  stress  is  present  in  depression,  which  could  poten-
ially  contribute  to  the  higher  risk  of  somatic  morbidity  and
ortality  in  sufferers.  There  is  a  need  for  future  larger  scale
tudies  on  oxidative  stress  in  depression,  in  which  the  role
f  treatment  effects  should  be  addressed.
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